Skip to content
No picture yet

Baxdela 450 mg – DIN 02554429

Baxdela is Delafloxacin Meglumine 450 mg (tablet), sold in Canada. It is used for bacterial infections and skin infections. It is supplied by Xediton Pharmaceuticals Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Delafloxacin Meglumine 450 mg

Brand
Baxdela
Strength
450 mg
Used for
Bacterial infections and skin infections
Form
Tablet
Manufacturer
Xediton Pharmaceuticals Inc
Drug class
Antibiotic (fluoroquinolone)
Sold in
Canada
DIN
02554429

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Delafloxacin Meglumine pills and guides

What is Delafloxacin Meglumine used for?

Delafloxacin Meglumine is used for bacterial infections and skin infections.

Medicine type
Antibiotic (fluoroquinolone)
Official uses from the US prescribing label

Acute Bacterial Skin and Skin Structure Infections

BAXDELA is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Community-Acquired Bacterial Pneumonia

BAXDELA is indicated in adults for the treatment of community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible [MSSA] isolates only), Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

From the FDA-approved label on DailyMed (published Aug 11, 2025).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02554429.
  • It names Baxdela, Delafloxacin Meglumine 450 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Baxdela by Xediton Pharmaceuticals Inc.

In Canada: prescription only.

Ingredients

Active: Delafloxacin (Delafloxacin Meglumine)

Other Delafloxacin Meglumine pills